In testimony before a Senate committee this week, a top US Food and
Drug Administration (FDA) official made the agency’s case for increased
powers to police drugs entering the US from abroad. “The FDA needs the
ability to refuse import of products from facilities that have delayed
or denied regulatory inspections,” FDA Deputy Commissioner for Global
Regulatory Operations Deborah Autor told committee members. Under
current rules, FDA must show reason to believe an imported product has
been adulterated or otherwise fails to meet FDA standards. Without
additional powers, Autor warned another Heparin-like crisis is
inevitable.
Read more: